The pharmaceutical payback mechanism in Italy requires companies to reimburse 50% of any overspending beyond a low annual ceiling, which is often set below actual needs. Industry leaders argue that recent government measures, particularly Article 57, threaten innovation and drug availability by reducing company margins in favor of distribution. Calls for a review of the payback system emphasize the need for a sustainable approach that supports pharmaceutical production and addresses potential drug shortages.
Marcello Cattani, president of Farmindustria, expressed disappointment over the lack of an increase in the pharmaceutical spending ceiling in Italy's budget maneuver, which he argues could lead to increased payback for companies and exacerbate drug shortages. He criticized Article 57 for reducing pharmaceutical margins in favor of distribution, calling for its repeal and emphasizing the need for a supportive industrial strategy to maintain Italy's competitiveness in the pharmaceutical sector. Cattani urged for a long-term vision to bring active ingredient production back to Europe and ensure rapid access to essential drugs.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.